Search research articles
Contact Us
Filters
Showing results (21-30 of 58) with videos related to
Page
of 6
Sort By:
Medical Oncology (Northwood, London, England)
|
April 3, 2012
Three different KRAS statuses in three synchronous colorectal cancers
L Jolissaint, W Cacheux, P Mariani, et al.
British Journal of Cancer
|
October 27, 2011
Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
G Bousquet, J Alexandre, C Le Tourneau, et al.
ESMO Open
|
December 26, 2021
Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapy
M Kerioui, S Desmée, F Mercier, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
August 2, 2018
Three-year results after radiotherapy for locally advanced sinonasal adenoid cystic carcinoma, using highly conformational radiotherapy techniques proton therapy and/or Tomotherapy
A Dautruche, S Bolle, L Feuvret, et al.
British Journal of Cancer
|
November 27, 2008
Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells
K A Benhadji, M Serova, A Ghoul, et al.
British Journal of Cancer
|
July 20, 2007
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells
M Serova, C M Galmarini, A Ghoul, et al.
ESMO Open
|
November 7, 2025
MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer
E Borcoman, A Hervieu, C Cropet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2014
A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials
A Doussau, R Thiébaut, B Geoerger, et al.
ESMO Open
|
August 5, 2023
Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens
P du Rusquec, R Guimbaud, K Le Malicot, et al.
ESMO Open
|
September 15, 2022
Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
C Le Tourneau, H Becker, R Claus, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 58) with videos related to
Sort By:
Page
of 6
Medical Oncology (Northwood, London, England)
|
April 3, 2012
Three different KRAS statuses in three synchronous colorectal cancers
L Jolissaint, W Cacheux, P Mariani, et al.
British Journal of Cancer
|
October 27, 2011
Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
G Bousquet, J Alexandre, C Le Tourneau, et al.
ESMO Open
|
December 26, 2021
Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapy
M Kerioui, S Desmée, F Mercier, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
August 2, 2018
Three-year results after radiotherapy for locally advanced sinonasal adenoid cystic carcinoma, using highly conformational radiotherapy techniques proton therapy and/or Tomotherapy
A Dautruche, S Bolle, L Feuvret, et al.
British Journal of Cancer
|
November 27, 2008
Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells
K A Benhadji, M Serova, A Ghoul, et al.
British Journal of Cancer
|
July 20, 2007
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells
M Serova, C M Galmarini, A Ghoul, et al.
ESMO Open
|
November 7, 2025
MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer
E Borcoman, A Hervieu, C Cropet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2014
A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials
A Doussau, R Thiébaut, B Geoerger, et al.
ESMO Open
|
August 5, 2023
Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens
P du Rusquec, R Guimbaud, K Le Malicot, et al.
ESMO Open
|
September 15, 2022
Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
C Le Tourneau, H Becker, R Claus, et al.
Page
of 6